Name of Journal: *World Journal of Stem Cells*

Manuscript NO: 58309

Manuscript Type: MINIREVIEWS

Targeting mesenchymal stem cell therapy for severe pneumonia patients

Guy Lam, Yuan Zhou, Jia-Xian Wang, Yat-Ping Tsui

Abstract

Pneumonia is the inflammation of the lungs and it is the world's leading cause of death for children under 5 years of age. The latest coronavirus disease 2019 (COVID-19) virus is a prominent culprit to severe pneumonia. With the pandemic running rampant for the past year, more than 1590000 deaths has occurred worldwide up to December 2020 and are substantially attributable to severe pneumonia and induced cytokine storm. Effective therapeutic approaches in addition to the vaccines and

336,000 Results Any time

Mesenchymal stem cell therapy for acute respiratory ...

https://pubmed.ncbi.nlm.nih.gov/32519302

SARS-CoV-2-infected **patients** with **severe pneumonia** rapidly develop acute respiratory distress syndrome (ARDS) and die of multiple org ... **Mesenchymal stem cell therapy** for acute respiratory distress syndrome: from basic to clinics

Cited by: 12 **Author:** Hua Qin, Andong Zhao
Publish Year: 2020

Mesenchymal stem cell therapy for acute respiratory ...

https://link.springer.com/article/10.1007/s13238-020-00738-2

Jun 09, 2020 · The 2019 novel coronavirus **disease** (COVID-19), caused by the **severe** acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has occurred in China and around the world. SARS-CoV-2-infected **patients** with **severe pneumonia** rapidly develop acute respiratory distress syndrome (ARDS) and die of multiple organ failure. Despite advances in supportive care approaches, ARDS is still associated with ...

Cited by: 12 **Author:** Hua Qin, Andong Zhao
Publish Year: 2020

An Exploratory Study of ADR-001 in Patients With Severe ...

https://clinicaltrials.gov/ct2/show/NCT04522986

Aug 21, 2020 · Patients with Severe Pneumonia caused by **SARS-CoV-2 infection** are enrolled to the study. Adipose-derived mesenchymal stem cells (AD-MSCs) are administered once a week, total four times intravenously. Safety and efficacy of AD-MSCs are evaluated for 12 weeks after first administer.

Using Stem Cells To Combat COVID-19 Pneumonia | Technology ...

https://www.technologynetworks.com/drug-discovery/...

Mar 31, 2020 · Researchers report that **intravenous transplantation** of human mesenchymal stem cells appears to be safe and effective for treatment in seven patients with **COVID-19 pneumonia**. Using Stem Cells To Combat COVID-19 Pneumonia. We've updated our Privacy Policyto make it clearer how we use your personal data.

Inhalation of Mesenchymal Stem Cells Exosomes Treating ...

https://www.amniowell.com/inhalation-of...

A **Pilot Clinical Study on Aerosol Inhalation of the Exosomes** Derived From Allogenic Adipose Mesenchymal Stem Cells in the Treatment of Severe Patients With Novel Coronavirus Pneumonia: Estimated Study Start Date: February 15, 2020: Estimated Primary Completion Date: May 31, 2020: Estimated Study Completion Date: July 31, 2020

Potential therapeutic application of mesenchymal stem cell ...

https://stemcellres.biomedcentral.com/articles/10.1186/s13287-020-01866-6

Aug 14, 2020 · Mesenchymal stem cell-derived **exosomes** (**MSC-Exo**) are believed to have anti-inflammatory effects and immune-modulating capacity as well as the ability to induce tissue regeneration, suggesting a significant therapeutic opportunity that could be used to SARS-CoV-2 pneumonia treatment.

MSC Therapies for COVID-19: Importance of Patient ...

https://www.frontiersin.org/articles/10.3389/fimmu.2020.01091

Numerous clinical trials of **mesenchymal** stromal/**stem cells** (MSCs) as a new **treatment** for coronavirus-induced **disease** (COVID-19) have been registered recently, most of them based on intravenous (IV) infusion. There is no approved effective **therapy** for COVID-19, but MSC therapies have shown first promise in the **treatment** of acute respiratory distress syndrome (ARDS) **pneumonia**, inflammation, ...

Treatment of severe COVID-19 with human umbilical cord ...

https://pubmed.ncbi.nlm.nih.gov/32811531

Background: COVID-19 is a highly infectious respiratory **disease**. No therapeutics have yet been proven effective for treating **severe** COVID-19. Objectives: To determine whether human umbilical cord **mesenchymal stem cell** infusion may be effective and safe for the **treatment** of **severe** COVID-19. Methods: **Patients** with **severe** COVID-19 were randomly divided into 2 groups: the standard **treatment** ...

Stem cell therapy for COVID-19: Possibilities and ...

https://onlinelibrary.wiley.com/doi/10.1002/cbin.11440

Recent use of **stem cells** for critically ill COVID-19 **patients** in a small group of **patients** in China and subsequent Emergency Use Authorization of **stem cells** by Food and Drug Administration to Global Institute of **Stem Cell Therapy** and Research and Athersys has ...

Treatment of severe COVID-19 with human umbilical cord ...

https://stemcellres.biomedcentral.com/articles/10.1186/s13287-020-01875-5

Aug 18, 2020 · COVID-19 is a highly infectious respiratory **disease**. No therapeutics have yet been proven effective for treating **severe** COVID-19. To determine whether human umbilical cord **mesenchymal stem cell** infusion may be effective and safe for the **treatment** of **severe** COVID-19. **Patients** with **severe** COVID-19 were randomly divided into 2 groups: the standard **treatment** group and the standard **treatment** ...

1 2 3 4 5 >

Search Tools

Turn off Hover Translation (关闭取词)

Microsoft Bing

Targeting mesenchymal stem cell therapy for severe pneumonia patients

ALL IMAGES VIDEOS MAPS NEWS SHOPPING

338,000 Results Any time

Mesenchymal stem cell therapy for acute respiratory ...

https://pubmed.ncbi.nlm.nih.gov/32519302

SARS-CoV-2-infected **patients** with **severe pneumonia** rapidly develop acute respiratory distress syndrome (ARDS) and die of multiple org ... **Mesenchymal stem cell therapy** for acute respiratory distress syndrome: from basic to clinics

Cited by: 12 **Author:** Hua Qin, Andong Zhao
Publish Year: 2020

Mesenchymal stem cell therapy for acute respiratory ...

https://link.springer.com/article/10.1007/s13238-020-00738-2

Jun 09, 2020 · The potential of MSC-based therapy in **COVID-19 patients** with severe pneumonia and ARDS by targeting **pathophysiological** changes. SARS-CoV-2 infections caused severe pneumonia and ARDS, with significant pathophysiological changes, including inflammation, immune system damages (leukopenia and lymphopenia), secondary infections, and distal organ injuries.

Cited by: 12 **Author:** Hua Qin, Andong Zhao
Publish Year: 2020

Can mesenchymal stem cell therapy be the interim ...

https://pubmed.ncbi.nlm.nih.gov/32554953

Severe health deterioration in critically ill **patients** is characterized by pulmonary edema, **severe** respiratory distress, cytokine storm and septic shock. To combat cytokine storm, immune-**therapy targeting** IL-1, IL-2, IL-6 and TNFα are being evaluated and one of the promising immune-modulator is the **mesenchymal stem cells** (MSCs) that can ...

Cited by: 1 **Author:** Chitra Bamba, Surinder P Singh, Sangeeta ...
Publish Year: 2020

Using Stem Cells To Combat COVID-19 Pneumonia | Technology ...

https://www.technologynetworks.com/drug-discovery/...